Every 10-Q that NexGel, Inc (NXGL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NXGL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NXGL filings page.
NexGel, Inc. reported higher revenue but significantly larger losses for the six months ended June 30, 2026. Revenue rose to $6.3 million from $5.7 million a year earlier, driven in part by new BioNx biomaterial products acquired through the Celularity license and asset purchase.
The company recorded a six‑month net loss attributable to stockholders of $4.6 million versus $1.4 million in 2025 and used $2.7 million in operating cash. Cash was $0.5 million with $1.2 million in restricted cash, while total liabilities rose to $21.0 million including $14.7 million of convertible debt and an $8.7 million derivative liability tied to conversion features. Management discloses that these conditions raise substantial doubt about the company’s ability to continue as a going concern and is relying on recently completed $8.6 million of Celularity‑related financing and future capital raises and growth from the BioNx portfolio to support operations.
NexGel, Inc. reported a larger quarterly loss and raised doubt about its ability to continue as a going concern. For the three months ended March 31, 2026, revenue was $2.65 million, down 5.6% from $2.81 million a year earlier, as branded consumer product sales declined.
Gross profit was $1.06 million with a 40.0% margin, compared with $1.19 million and 42.3% a year ago. Net loss attributable to NexGel stockholders widened to $927,000 (basic and diluted loss per share of $0.11) from $712,000 ($0.09 per share).
As of March 31, 2026, NexGel held $208,000 in cash and $1.91 million in restricted cash, and used $504,000 in operating cash during the quarter. Management concluded these conditions raise substantial doubt about long‑term viability, though subsequent financings and strategic initiatives are intended to improve liquidity.
NexGel, Inc. (NXGL) filed its Q3 2025 report, showing steady quarterly results and a continued focus on consumer brands alongside contract manufacturing. Revenue for the quarter was $2.934 million versus $2.940 million a year ago, while nine‑month revenue rose to $8.625 million from $5.647 million. Q3 gross profit was $1.243 million. The net loss attributable to stockholders was $653,000, or $0.08 per share, an improvement from $693,000 (or $0.11) last year.
The company disclosed substantial doubt about its ability to continue as a going concern. At September 30, cash was $938,000, alongside $920,000 of partnership restricted cash. Operating cash use for the nine months was $1.592 million, and working capital was $2.3 million. During Q3, NexGel raised equity proceeds of $963,000 by issuing 458,695 shares. Shares outstanding were 8,142,766 as of September 30, and 8,143,133 as of November 12, 2025.
Segment mix for Q3 included $1.918 million from consumer branded products and $907,000 from contract manufacturing.